^
CANCER:

Rectal Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Rectal Cancer
FOLFIRI
Sensitive
:
A1
No biomarker
Rectal Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Rectal Cancer
irinotecan
Sensitive
:
A1
No biomarker
Rectal Cancer
bevacizumab-maly
Sensitive
:
A1
No biomarker
Rectal Cancer
CT-P16 (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Rectal Cancer
nivolumab
Sensitive
:
A2
No biomarker
Rectal Cancer
FOLFIRINOX
Sensitive
:
A2
No biomarker
Rectal Cancer
capecitabine
Sensitive
:
A2
No biomarker
Rectal Cancer
FOLFOX
Sensitive
:
A2
MSI-H/dMMR
Rectal Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Rectal Cancer
CAPOX
Sensitive
:
A2
No biomarker
Rectal Cancer
bevacizumab
Sensitive
:
A2
No biomarker
Rectal Cancer
5-fluorouracil
Sensitive
:
A2
MSI-H/dMMR
Rectal Cancer
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Rectal Cancer
trifluridine / tipiracil
Sensitive
:
A2
HER-2 amplification
Rectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
NTRK3 fusion
Rectal Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Rectal Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Rectal Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Rectal Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Rectal Cancer
entrectinib
Sensitive
:
A2
NTRK3 fusion
Rectal Cancer
entrectinib
Sensitive
:
A2
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive
:
A2
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive
:
A2
No biomarker
Rectal Cancer
ramucirumab
Sensitive
:
A2
No biomarker
Rectal Cancer
ziv-aflibercept IV
Sensitive
:
A2
No biomarker
Rectal Cancer
5-fluorouracil + leucovorin calcium
Sensitive
:
A2
No biomarker
Rectal Cancer
mFOLFOX6
Sensitive
:
A2
No biomarker
Rectal Cancer
regorafenib
Sensitive
:
A2
KRAS wild-type
Rectal Cancer
panitumumab
Sensitive
:
A2
No biomarker
Rectal Cancer
mFOLFOX7
Sensitive
:
A2
NRAS wild-type
Rectal Cancer
panitumumab
Sensitive
:
A2